Chronic Myelogenous Leukemia, Version 1.2015

Abstract

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• Northwestern University US
• University of Utah US
• University of Tennessee Health Science Center US
• Stanford University US
• City Of Hope National Medical Center US
• University of Alabama at Birmingham US
• University of California, San Diego US
• Duke Cancer Institute
• University of Nebraska–Lincoln US
• The Ohio State University US
• Fox Chase Cancer Center US
• Vanderbilt University US
• The University of Texas MD Anderson Cancer Center US
• Johns Hopkins University US
• Duke University US
• University of California, San Francisco US
• Washington University in St. Louis US
• Memorial Sloan Kettering Cancer Center US
• Seattle Cancer Care Alliance US
• Harvard University Press US
• Roswell Park Comprehensive Cancer Center US

Related Publications